克罗恩病肛瘘研究进展

Progress in Research on Perianal Fistulizing Crohn’s Disease

肛瘘是克罗恩病患者长期不良预后的预测因素,克罗恩病肛瘘(pfCD)严重影响患者的生命质量。pfCD的治疗提倡手术与药物治疗相结合,生物制剂尤其是TNF-α抑制剂的出现,极大地改善了pfCD患者的预后。近年发现一些新型生物制剂、间充质干细胞等治疗方式有助于缓解病情,对于复杂性肛瘘,保留括约肌等术式可极大减少尿失禁等术后并发症,给pfCD患者带来新的希望。本文就pfCD的诊治进展作一综述。

Perianal fistula is a predictor of long⁃term poor prognosis in patients with Crohn’s disease,and perianal fistulizing Crohn’s disease(pfCD)seriously affects the quality of life of patients.The treatment of pfCD advocates a combination of surgery and drug therapy.The advent of biologic agents,especially TNF⁃αagents,has greatly changed the prognosis of patients with pfCD.In recent years,some new biological agents and mesenchymal stem cells have also been shown to contribute to the remission of the disease.For complex perianal fistula,preservation of sphincter has greatly reduced postoperative complications such as urinary incontinence,bringing new hope to pfCD patients.This article reviewed the progress in research on the diagnosis and treatment of pfCD.